Leqembi wins EU authorization for some Alzheimer's patients, giving Biogen, Eisai a boost over Lilly
European regulators on Tuesday authorized the use of Biogen and Eisai’s Alzheimer’s treatment Leqembi for some early-stage patients “under strict conditions.”
The decision from the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
